Molecular and cytogenetic analyses on Brazilian youths with pervasive developmental disorders.

Doctors in Brazil looked at the chromosomes of 30 youths who had pervasive developmental disorders. They used blood tests and microscopes to spot large missing or extra pieces of DNA.

The kids were already diagnosed with autism or similar delays. No treatment was tested; the team only wanted to see how often gene errors show up.

Four kids—about one in every seven—carried clear chromosomal problems. One boy had fragile X syndrome, one girl carried an extra copy of the Prader-Willi/Angelman region, and two others held odd rearrangements.

These findings gave families a medical reason for the delays and pointed them to specific care guidelines.

Gaily et al. (1998) ran a similar screen on the children and found defects in only a large share. The jump from a large share to a large share looks like a contradiction, but the earlier study used older lab methods that missed smaller changes. Better techniques explain the higher hit rate.

Hong et al. (2021) swapped microscopes for high-resolution microarrays and still found about a large share of kids with non-syndromic delays had clear genetic answers. The close match supports the Brazilian figure and shows the value of modern tools.

Cohen et al. (2005) pulled the evidence together in a review and now recommends starting with a clinical checklist, then ordering genetic tests—exactly the pathway this Brazilian team followed.

If you evaluate a child for autism, add a genetic referral to the plan when delays are unexplained. A simple blood test can reveal fragile X, 15q duplication, or other treatable syndromes, giving families precise prognosis, carrier counseling, and access to targeted supports.